Companies › Incyclix Bio
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| INX-315 CDK2 inhibitor | CDK2 | Phase 1 | Breast Cancer | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05735080 | INX-315 | Phase 1 | Breast Cancer | Oncology | Jul 2027 |
NiKang Therapeutics Avenzo Therapeutics Chia Tai Tianqing Pharmaceutical Group BeiGene AstraZeneca Eilean Therapeutics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.